# An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

> **NCT02811159** · PHASE2 · TERMINATED · sponsor: **Repros Therapeutics Inc.** · enrollment: 20 (actual)

## Conditions studied

- Uterine Fibroids

## Interventions

- **DRUG:** Telapristone acetate

## Key facts

- **NCT ID:** NCT02811159
- **Lead sponsor:** Repros Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-07-26
- **Primary completion:** 2017-05-04
- **Final completion:** 2017-05-04
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2019-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02811159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02811159, "An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02811159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*